SOA Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

SOA Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.8K	Hold	78	–	–	0.01%	426
2025 Q4	$35.4K	Hold	78	–	–	0.01%	419
2025 Q3	$30.5K	Sell	78 -11	-12%	-$4.6K	0.01%	449
2025 Q2	$39.6K	Sell	89 -2	-2%	-$922	0.01%	404
2025 Q1	$44.1K	Hold	91	–	–	0.01%	360
2024 Q4	$36.6K	Hold	91	–	–	0.01%	372
2024 Q3	$42.3K	Buy	91 +11	+14%	+$5.28K	0.01%	347
2024 Q2	$37.5K	Hold	80	–	–	0.01%	346
2024 Q1	$33.4K	Hold	80	–	–	0.01%	359
2023 Q4	$32.6K	Hold	80	–	–	0.01%	349
2023 Q3	$27.8K	Hold	80	–	–	0.01%	361
2023 Q2	$28.2K	Hold	80	–	–	0.01%	373
2023 Q1	$25.2K	Hold	80	–	–	0.01%	384
2022 Q4	$23.1K	Sell	80 -1	-1%	-$305	0.01%	381
2022 Q3	$23K	Hold	81	–	–	0.01%	363
2022 Q2	$22K	Sell	81 -26	-24%	-$6.96K	0.01%	372
2022 Q1	$27K	Hold	107	–	–	0.01%	407
2021 Q4	$23K	Hold	107	–	–	0.01%	431
2021 Q3	$19K	Sell	107 -8	-7%	-$1.56K	﹤0.01%	472
2021 Q2	$23K	Buy	115 +14	+14%	+$2.93K	0.01%	439
2021 Q1	$21K	Buy	101 +9	+10%	+$1.98K	0.01%	399
2020 Q4	$19K	Buy	+92	New	+$21.1K	0.01%	419

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SOA Wealth Advisors's VRTX Position: Q1 2026 in Review

SOA Wealth Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 78 shares worth $34.8K. The position accounts for 0.01% of the portfolio, ranked #426.

SOA Wealth Advisors first reported a position in VRTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $44.1K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

SOA Wealth Advisors held 78 shares of Vertex Pharmaceuticals worth $34.8K as of Q1 2026.
SOA Wealth Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of SOA Wealth Advisors's portfolio in Q1 2026, its #426 holding.
SOA Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
SOA Wealth Advisors's Vertex Pharmaceuticals position peaked at $44.1K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SOA Wealth Advisors's 13F filing for Q1 2026, filed 20 May 2026.